TABLE 3.
Characteristics of neonates receiving the simplified dosing regimen in the Amsterdam UMC and the complex dosing regimen in University Hospitals Leuven (9)e
| Characteristica | Simplified dosing regimen (n = 366) | Complex dosing regimen (n = 579) | P value |
|---|---|---|---|
| Male, n (%) | 216 (59%) | 324 (56%) | 0.62 |
| GA, weeksb | 28.7 (24.0–42.1) | 34 (24–41) | <0.01 |
| GA < 30 weeks, n (%) | 209 (56.9%) | 91 (15.7%) | |
| GA ≥ 30 weeks, n (%) | 158 (43.1%) | 489 (84.3%) | |
| GA ≥ 37 weeks, n (%) | 46 (12.5%) | 212 (36.6%) | |
| PNA (days)c | 9 (0–31) | 2 (1–30) | <0.01 |
| PMA (weeks)c | 30.2 (24.6–44.6) | 34 (24–54) | <0.01 |
| Birth weight (g)b | 1,100 (440–5,200) | 2,150 (420–4,850) | <0.01 |
| Current weight (g)c | 1,100 (455–5,500) | 2,120 (420–5,040) | <0.01 |
| SCr (μmol/L)c,d | 42 (11–194) | 88 (11–316) | <0.01 |
| Co-administration of ibuprofen, n (%)c | 7 (2%) | 29 (5%) | <0.01 |
| Total number of samples | 768 | 1,195 | |
| Cmin samples, n (%) | 242 (32%) | 741 (62%) | |
| Cmax samples, n (%) | 402 (52%) | 417 (35%) | |
| BLQ samples, n (%) | 61 (7.9%) | 52 (4.4%) |
Baseline characteristics are depicted by median and range for continuous variables and percentages for categorical variables.
Measured at birth.
Measured around amikacin administration.
Creatinine measured in n = 302 neonates (simplified dosing regimen) and n = 571 neonates (complex dosing regimen).
GA, gestational age; BLQ, below limit of quantification; Cmax, peak concentration (defined as time after amikacin dose < 2 hours); Cmin, trough concentration (defined as time after amikacin dose > 20 hours); n, number; PMA, postmenstrual age; PK, pharmacokinetic; PNA, postnatal age; SCr, serum creatinine.